[18F]Tetrafluoroborate, a new NIS PET/CT radiopharmaceutical: an overview focused on differentiated thyroid cancer
European Thyroid Journal · 2025
DOI: 10.1530/etj-24-0320 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Thyroid Journal, 2025. Verfasst von Arnoldo Piccardo und 11 weiteren Autor:innen. Beteiligte Einrichtung: S.C. di Medicina Nucleare, Galliera Hospital, Genoa, Italy. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Positron Emission Tomography Computed Tomography, Radiopharmaceuticals, Symporters. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
In relapsing differentiated thyroid cancer (DTC), the in vivo evaluation of natrium–iodide symporter (NIS) expression is pivotal in the therapeutic planning and is achieved by 131/123 Iodine ( 131/123 I) whole body scan. However, these approaches have low sensitivity due to the low resolution of SPECT. 18 F-Tetrafluoroborate (TFB) has been proposed as a viable alternative, which could outperform 131/123 I scans owing to the superior PET resolution. We have reviewed the literature to collect the available data on TFB diagnostic performance and compare it with the standard methods.
Methods
Two authors searched PubMed, CENTRAL, Scopus, Web of Science and the web for studies evaluating the biodistribution and dosimetry of TFB in patients with DTC. General characteristics, technical parameters, procedures’ sensitivities and standards of reference were extracted from the selected studies. The risk of bias was evaluated with the QUADAS-2 scoring system.
Results
Five studies were included in the review. Two analysed TFB’s biodistribution and dosimetry, while the other three assessed its diagnostic performance. The diagnostic comparators were 18 F-FDG PET/CT (all cases), 124 I-PET/CT (one study) and diagnostic/therapeutic 131 I-SPECT/CT (one study each). TFB performed better than 131 I; the TFB and 18 F-FDG PET/CT combination achieved the best sensitivity. TFB delivered significantly less dose than the other NIS tracers.
Conclusion
TFB is a promising tracer in relapsing DTC, showing higher sensitivity and less radiation exposure than the standard methods. The TFB and 18 F-FDG combination appears particularly intriguing, especially when disease heterogeneity is suspected. However, data are still sparse and need to be confirmed by further investigations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- S.C. di Medicina Nucleare, Galliera Hospital, Genoa, Italy.
- Centro della Tiroide, "Galliera Hospital", Genoa, Italy.
- S.S.D. Fisica Medica, Galliera Hospital, Genoa, Italy.
- Department of Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
- Department of Health Sciences, University of Genoa, Italy.
- Department of Nuclear Medicine, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
ORCID-Profile: Francesco Fiz
Zitieren
APA
Piccardo, A., Fiz, F., Righi, S., Raffa, S., Riondato, M., Bottoni, G., Bauckneht, M., Massollo, M., Rizzo, A., Naseri, M. S. Z., Trimboli, P., & Treglia, G. (2025). [18F]Tetrafluoroborate, a new NIS PET/CT radiopharmaceutical: an overview focused on differentiated thyroid cancer. European Thyroid Journal. https://doi.org/10.1530/etj-24-0320
Vancouver
Piccardo A, Fiz F, Righi S, Raffa S, Riondato M, Bottoni G, et al. [18F]Tetrafluoroborate, a new NIS PET/CT radiopharmaceutical: an overview focused on differentiated thyroid cancer. European Thyroid Journal. 2025. doi:10.1530/etj-24-0320
BibTeX
@article{Piccardo2025,
author = {Piccardo, Arnoldo and Fiz, Francesco and Righi, Sergio and Raffa, Stefano and Riondato, Mattia and Bottoni, Gianluca and Bauckneht, Matteo and Massollo, Michela and Rizzo, Alessio and Naseri, Mehrdad Shoushtari Zadeh and Trimboli, Pierpaolo and Treglia, Giorgio},
title = {[18F]Tetrafluoroborate, a new NIS PET/CT radiopharmaceutical: an overview focused on differentiated thyroid cancer},
journal = {European Thyroid Journal},
year = {2025},
doi = {10.1530/etj-24-0320}
}
EUVIMED